|Dr. Yuval Cohen Ph.D.||CEO & Director||890.67k||N/A||1975|
|Mr. Sean F. Moran CPA, M.B.A.||Chief Financial Officer||579.05k||N/A||1958|
|Dr. Rachael Brake Ph.D.||Chief Scientific Officer||552.22k||N/A||1972|
|Ted Jenkins||Senior Director of Investor Relations & Corporate Communications||N/A||N/A||N/A|
|Ms. Lindsey Smith||Head of Corporate Communications & Patient Advocacy||N/A||N/A||N/A|
|Ms. Christina Bertsch||Head of Human Resources||N/A||N/A||N/A|
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 4; Compensation: 9.